fda approved kinase inhibitor library

263种靶向激酶的上市药物集合，用于特定靶向激酶，可用于高通量筛选和高内涵筛选；

1147 种与离子通道相关的生物活性小分子化合物的特有集合，用于离子通道相关的疾病和药物研究，可用于高通量筛选和高内涵筛选；

604 个与细胞因子紧密相关的化合物集合，是高通量、高内涵筛选的良好载体；

1729 个FDA 批准药物的独特集合，可用于高通量筛选和高内涵筛选；

2720 种激酶抑制剂 调节剂的独特集合，用于特定靶向激酶，可用于高通量筛选和高内涵筛选；

3158 个上市及药典分子集合，可用于高通量筛选和高内涵筛选；

2808 个上市药物化合物集合，可用于高通量筛选和高内涵筛选；

485 种已知活性的 PPI 相关的抑制剂，可用于高通量、高内涵筛选；

343 种已知的小分子蛋白酶抑制剂的特有集合，可用于高通量筛选和高内涵筛选；

1920 种小分子的独特集合，包含已发现的共价抑制剂以及包含某些共价反应基团常见弹头的分子，如氯乙酰基，2-氯丙酰基，丙烯酰基，1-丙-2-炔基，1-丁-2-炔基，酮羰基，二硫键等，可以用于共价抑制剂药物研发；

8328 个小分子抑制剂的独特集合，主要用于细胞信号研究、新药筛选、高通量筛选和高内涵筛选；

79 种已知活性的磷酸酶抑制剂的集合，可用于化合物筛选、化学基因组学、药理分析等方面；

59 种趋化因子或其受体抑制剂的独特集合，可用于高通量筛选和高内涵筛选；

1779 个具有抗癌活性小分子的独特集合，所有化合物都经过了严格的临床前研究和临床试验，由FDA、EMA 或NMPA 批准上市，可用于高通量、高内涵筛选。

365 种与MAPK 信号通路相关的生物活性小分子化合物的特有集合，可用于高通量筛选和高内涵筛选；

Life Chemicals has designed a proprietary Kinase Targeted Docking Library of over 13,000 drug-like screening compounds.

The total number of compounds in the Phosphatidylinositol 3-Kinase (PI3K) Targeted Library is 939.

Over 1,900 structurally diverse screening compounds, capable of fitting the cytochrome binding site to form donor acceptor bonds and produce CYP inhibition, were selected from the HTS Compound Collection.

The total number of compounds in the library is over 590.

Thymidine kinase inhibitor library in Otava contains 922 compounds

MAO B inhibitor library in Otava contains 182 compounds

Aurora C kinase inhibitor library in Otava contains 1162 compounds

Protein kinase CK1 inhibitor library in Otava contains 1387 compounds

OTAVAchemicals DOT1L Targeted Library (622 compounds) has been carefully designed with a receptor-based approach that included docking of Drug-like Green Collection in the active site of human DOT1L (crystal structure of the complex with inhibitor FED2, PDB ID 4EQZ)

Cyclin-dependent kinase 2 (CDK2) inhibitor library contains 670 compounds.

GSK3 inhibitors might also have the potential for neurodegenerative disorders, such as Alzheimer's disease. Glycogen synthase kinase 3 (GSK3) inhibitor library contains 479 compounds.

Proto-oncogene tyrosine protein kinase Kit inhibitor library in Otava contains 214 compounds

DNA (cytosine-5)-methyltransferase 1 (DNMT1) inhibitor library contains 466 compounds.

Smooth muscle myosin light chain kinase (MLCK) inhibitor library in Otava contains 627 compounds

EphB2 kinase inhibitor library in Otava contains 329 compounds

Janus kinase 2 (Jak2) inhibitor library in Otava contains 625 compounds.

P21-activated kinase 1 (PAK1) inhibitor library in Otava contains 606 compounds.

Glycogen synthase kinase-3 beta (GSK3B) inhibitor library in Otava contains 521 compounds

p38 MAP kinase alpha targeted library in Otava contains 592 compounds.

There are 4817 compounds in Signal Pathway Inhibitor Library.

Rho-associated kinase inhibitor library in Otava contains 344 compounds

Phosphatidylinositol 3-kinase C2 gamma (PI3K-C2 gamma) inhibitor library in Otava contains 252 compounds

DNA (cytosine-5)-methyltransferase 3 beta (DNMT3b) inhibitor library contains 1261 compounds.

It comprises over 2,500 drug-like screening compounds of potential anaplastic lymphoma kinase inhibitors.

C-Jun N-terminal kinase 2 (Jn2) inhibitor library in Otava contains 1774 compounds

3-phosphoinositide-dependent Kinase 1 (PDK-1) Targeted Library contains 496 compounds.

iPPI Tree Library with 1211 compounds was designed with a decision tree algorithm based on several molecular shapes and functional group descriptors.

Death-associated protein kinase 1 (DAPK1) inhibitor library in Otava contains 1962 compounds

Serine threonine kinase CHK1 inhibitor library in Otava contains 681 compounds.

Shikimate kinase inhibitor library in Otava contains 453 compounds

Death-associated kinase 2 (DAPK2) inhibitor library contain 591 compounds.